共 414 条
[1]
Sospedra M(2005)Immunology of multiple sclerosis Annu Rev Immunol 23 683-747
[2]
Martin R(2006)A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899-910
[3]
Polman CH(2003)A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 15-23
[4]
O’Connor PW(2010)Anti-JC virus antibodies: implications for PML risk stratification Ann Neurol 68 295-303
[5]
Havrdova E(2012)Risk of natalizumab-associated progressive multifocal leukoencephalopathy N Engl J Med 366 1870-1880
[6]
Hutchinson M(2013)L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients Neurology 81 865-871
[7]
Kappos L(2014)Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy Ann Neurol 76 802-812
[8]
Miller DH(2011)Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis Neurology 76 1858-1865
[9]
Phillips JT(2014)MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study Neurology 82 1491-1498
[10]
Lublin FD(2015)Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE J Neurol 262 326-336